TOBIN domain · IMM
Inflammation / Infections / Immune Dysregulation
Innate and adaptive immunity, inflammatory pathways, allergy, autoimmunity, mast-cell activity, microbiome disruption and clinically relevant infections.
Full description
Inflammation / Infections covers the immune system: chronic low-grade inflammation, allergy and atopy, autoimmunity, and the Fifth Estate — bacteria, viruses, fungi and parasites, both as infections and as the microbiome.
Chronic low-grade inflammation is common to cardiovascular disease, diabetes, depression and many cancers. This domain links to the Allergy/Immune Complex pandemic (Quadpandemic III).
Components
5 componentsChronic low-grade inflammation
ALong-term mild increases in CRP, IL-6 and TNF-α, often from belly fat, smoking, poor sleep and diet.
How it works: Fat-tissue macrophages and the innate immune system release cytokines that impair insulin signaling and blood vessels.
How it is assessed
- · hs-CRP (above 3 mg/L is high cardiovascular risk; above 10 suggests acute illness)
- · White blood cell count
Allergy and atopy
BAsthma, eczema, hay fever and food allergy — IgE-mediated type 2 immunity.
How it works: Barrier damage (skin, gut, airway), less microbial diversity early in life (hygiene and 'old friends' hypotheses) and pollutants all push the immune system toward allergy.
How it is assessed
- · Eosinophils, total IgE
- · Spirometry; specific IgE or skin-prick testing
Autoimmunity
BHashimoto's, celiac disease, rheumatoid arthritis, lupus and type 1 diabetes — about 80% of cases are in women.
How it works: Genetic susceptibility plus triggers: infection (EBV and multiple sclerosis — strong causal evidence), smoking, low vitamin D.
How it is assessed
- · Disease-specific antibodies (anti-TPO, tTG-IgA, ANA) when symptoms suggest it
Fifth Estate: infections and microbiome
BAcute and chronic infections (H. pylori, hepatitis, periodontal disease, post-viral syndromes) and the gut microbiome as an organ.
How it works: Persistent infection keeps the immune system activated; dysbiosis and gut leakiness increase circulating endotoxin.
How it is assessed
- · Infection-specific testing when clinically indicated
- · Oral health review
- · Stool testing only for specific indications
Gut barrier
CThe gut lining separates microbes from the immune system.
How it works: Diet low in fiber, alcohol, NSAIDs and stress weaken tight junctions; short-chain fatty acids from fiber support them.
How it is assessed
- · Digestive symptoms; celiac serology
Clinical bottom line: Strong evidence supports treating infections that are actually confirmed, quitting smoking, the Mediterranean diet, exercise, weight loss and sleep for lowering inflammation. Antibiotics or antifungals based only on a microbiome pattern are not supported.
What it covers
- · Allergy & atopy
- · Autoimmune activity
- · Mast-cell & eosinophilic patterns
- · Microbiome disruption
- · Bacterial, viral, fungal & parasitic findings
Symptoms and exposures scored
5 questions- · How often do you have allergy symptoms — sneezing, itching, hives, wheeze or eczema?
- · How often do you need antihistamines, inhalers or steroids for these symptoms?
- · How often do you have bloating, pain, urgency or irregular stools?
- · How often do you get infections needing antibiotics or antivirals?
- · How often do you have joint pain, stiffness or swelling?
Lab ranges
Graded 0–100 against published cutoffs| Test | Grading points (value → concern 0–100) | Source |
|---|---|---|
| hs-CRPmg/L · higher is worse | 1→0 3→60 10→100systemic inflammation | AHA/CDC: <1 lower, 1–3 average, >3 higher cardiovascular-inflammatory risk; >10 suggests acute process |
| Ferritinng/mL · higher is worse | 300→0 500→50 1000→100inflammation or iron overload (high) | AGA 2020: ferritin <45 ng/mL supports iron deficiency; WHO <15 depleted |
| Eosinophils (absolute)cells/µL · higher is worse | 500→0 1500→70 3000→100eosinophilic / allergic activity | >500 cells/µL eosinophilia; ≥1500 hypereosinophilia |
| Total IgEIU/mL · higher is worse | 100→0 400→60 1000→100atopic sensitization | Adult reference typically <100 IU/mL; context-dependent |
| White blood cells×10³/µL · higher is worse | 11→0 15→60 20→100immune activation | Reference ≈ 4.0–11.0 ×10³/µL |
| Anti-TPO antibodiesIU/mL · higher is worse | 34→0 35→40 100→70 500→100thyroid autoimmunity | Common cutoff >34–35 IU/mL (assay-specific); marks Hashimoto's risk (ATA) |
| Thyroglobulin antibodiesIU/mL · higher is worse | 4→0 5→40 40→70 200→100thyroid autoimmunity | Common cutoff ≤4 IU/mL (Roche) — assay-specific; positive in ~60–80% of Hashimoto's |
| Lp-PLA2 activitynmol/min/mL · higher is worse | 123→0 150→50 225→100vascular inflammation | PLAC Activity test (FDA-cleared): >123 nmol/min/mL higher risk |
Formulas
- Symptom score = average answer (0–4) × 25
- Lab score = 0.6 × worst marker + 0.4 × average marker
- I score = 60% symptoms + 40% labs (whichever exists if only one)
- Bands: 0–33 lower · 34–66 moderate · 67–100 higher
Symptom score = average of your answers in that domain (0–4 scale, shown as 0–100). Lab score = 0.6 × the most out-of-range marker + 0.4 × the average of that domain's markers, where each marker is graded 0–100 against published clinical cutoffs. When both exist, the domain score = 60% symptoms + 40% labs. If you logged your journal in the last 14 days, 20% of the score comes from it: daily symptoms (I, O), sleep under 7 hours (O, B), low energy (N, O) and low mood (B).
Conditions where this domain weighs heavily
iClinical organizational scores based on the TOBIN framework. They group signals for review and are not validated diagnostic instruments or a medical diagnosis.
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.